

## FOR IMMEDIATE RELEASE

### THERAPEUTICSM D ANNOUNCES PRICING OF COMMON STOCK OFFERING

**Boca Raton, FL, July 9, 2015** – TherapeuticsMD, Inc. (NYSE MKT: TXMD) today announced the pricing of an underwritten public offering of approximately 3.8 million shares of its common stock, offered at a price of \$7.80 per share. The gross proceeds to TherapeuticsMD from this offering are expected to be approximately \$30.0 million, before deducting underwriting discounts, commissions and other offering expenses payable by TherapeuticsMD. In addition, TherapeuticsMD has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to approximately 577,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is expected to close on or about July 15, 2015, subject to the satisfaction of customary closing conditions.

Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering.

TherapeuticsMD intends to use a majority of the proceeds of the offering to partially fund validation and qualification of a secondary manufacturing source for its TX-001HR and TX-004HR drug candidates, as well as continued validation and scale-up of the manufacturing processes for these drug candidates, and for other research, clinical formulation and development and general corporate purposes.

TherapeuticsMD has filed a shelf registration statement on Form S-3, including a prospectus supplement and accompanying prospectus, with the Securities and Exchange Commission (the “SEC”), relating to the public offering of the shares of common stock described above. Before buying any shares of TherapeuticsMD’s common stock in the offering, you should carefully read the prospectus supplement and the accompanying prospectus, together with the information incorporated therein. These documents contain important information that you should consider when making your investment decision. TherapeuticsMD’s SEC filings are available to the public from the SEC’s website at [www.sec.gov](http://www.sec.gov). When available, copies of the prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting one of the following Stifel, Nicolaus & Company, Incorporated, Attn: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by calling (415) 364-2720 or by emailing [syndprospectus@stifel.com](mailto:syndprospectus@stifel.com), or Guggenheim Securities, LLC, Equity Syndicate Department, 330 Madison, 8th Floor, New York, NY 10017, or by telephone at (212) 518-9658, or by email to [GSEquityProspectusDelivery@guggenheimpartners.com](mailto:GSEquityProspectusDelivery@guggenheimpartners.com).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

#### **About TherapeuticsMD, Inc.**

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its patented SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s clinical development pipeline includes two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins under the vitaMedMD® and BocaGreenMD® brands.

## **Forward Looking Statements**

*This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD's objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that TherapeuticsMD intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and TherapeuticsMD undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of TherapeuticsMD's control. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering, risks and uncertainties associated with TherapeuticsMD's business and finances in general and other risks described in the sections titled "Risk Factors" in TherapeuticsMD's filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K. PDF copies of TherapeuticsMD's historical press releases and financial tables can be viewed and downloaded at its website: [www.therapeuticsmd.com/pressreleases.aspx](http://www.therapeuticsmd.com/pressreleases.aspx).*

###

### **Contact:**

Daniel A. Cartwright  
Chief Financial Officer  
561-961-1900  
Dan.Cartwright@TherapeuticsMD.com